A new Spanish study on the mixing of vaccines against COVID-19 sees the light of day and accordingly, giving a dose of Pfizer / Biontech to people who have already taken the first dose of AstraZeneca is extremely safe and effective.
The so-called Combivacs study, conducted by the Spanish government-supported Carlos III Health Institute, found that The immune response in people receiving Pfizer was 30 to 40 times higher than in a control group receiving a dose of AstraZeneca alone.
A few serious side effects were reported among the 600 participants, said the authors of the study, as broadcast by Reuters.
Meanwhile, A new study conducted by EKPA focused on the production of neutralizing antibodies from coronavirus vaccines. Scientists are comparing the antibodies produced after the administration of Pfizer and AstraZeneca, explaining to the public what is true.
The results of 78 people who received the Pfizer vaccine were compared with those of 73 volunteers who received the AstraZeneca vaccine. Prior to the first dose of the vaccine, there was no difference in the value of the neutralizing antibodies between the two groups. On day 22, before the second dose of the Pfizer vaccine, 78% of those vaccinated with the Pfizer vaccine developed neutralizing antibodies, compared with 56% of those who received the AstraZeneca vaccine.
On the 50th day, that his team Pfizer vaccine had already received the second dose of the vaccine and had passed a period of 4 weeks, the difference as the Athenian News Agency points out was even greater. Overall, 98% of those vaccinated with the Pfizer vaccine developed neutralizing antibodies (almost all at levels above 75%) versus 75% of those who received the AstraZeneca vaccine. In the AstraZeneca vaccine group, only 11% had neutralizing antibody titers above 75%, 50 days after the first dose of the vaccine. However, as the results show, there was an increase in the number of people with positive antibody titers and with the AstraZeneca vaccine, between 3 and 7 weeks after the first dose of the vaccine.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
